ATE257378T1 - Phenylacetylglutamin, phenylacetylisoglutamin, und/oder phenylacetat zur behandlung von neoplastischen erkrankungen - Google Patents

Phenylacetylglutamin, phenylacetylisoglutamin, und/oder phenylacetat zur behandlung von neoplastischen erkrankungen

Info

Publication number
ATE257378T1
ATE257378T1 AT99932179T AT99932179T ATE257378T1 AT E257378 T1 ATE257378 T1 AT E257378T1 AT 99932179 T AT99932179 T AT 99932179T AT 99932179 T AT99932179 T AT 99932179T AT E257378 T1 ATE257378 T1 AT E257378T1
Authority
AT
Austria
Prior art keywords
phenylacetylisoglutamin
treatment
pharmaceutical composition
phenyl acetate
neoplastic diseases
Prior art date
Application number
AT99932179T
Other languages
German (de)
English (en)
Inventor
Stanislaw R Burzynski
Original Assignee
Stanislaw R Burzynski
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stanislaw R Burzynski filed Critical Stanislaw R Burzynski
Application granted granted Critical
Publication of ATE257378T1 publication Critical patent/ATE257378T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
AT99932179T 1998-07-23 1999-07-02 Phenylacetylglutamin, phenylacetylisoglutamin, und/oder phenylacetat zur behandlung von neoplastischen erkrankungen ATE257378T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/121,567 US6258849B1 (en) 1998-07-23 1998-07-23 Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate
PCT/US1999/015017 WO2000004894A2 (en) 1998-07-23 1999-07-02 Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate

Publications (1)

Publication Number Publication Date
ATE257378T1 true ATE257378T1 (de) 2004-01-15

Family

ID=22397538

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99932179T ATE257378T1 (de) 1998-07-23 1999-07-02 Phenylacetylglutamin, phenylacetylisoglutamin, und/oder phenylacetat zur behandlung von neoplastischen erkrankungen

Country Status (20)

Country Link
US (2) US6258849B1 (enExample)
EP (1) EP1098643B1 (enExample)
JP (2) JP2002521329A (enExample)
KR (4) KR100399658B1 (enExample)
CN (3) CN1605334A (enExample)
AT (1) ATE257378T1 (enExample)
AU (1) AU759278B2 (enExample)
BR (1) BR9912356A (enExample)
CA (1) CA2336945C (enExample)
DE (1) DE69914084T2 (enExample)
DK (1) DK1098643T3 (enExample)
EA (1) EA004179B1 (enExample)
ES (1) ES2214866T3 (enExample)
ID (1) ID28160A (enExample)
IL (1) IL140848A (enExample)
NZ (1) NZ509244A (enExample)
PL (1) PL213698B1 (enExample)
PT (1) PT1098643E (enExample)
WO (1) WO2000004894A2 (enExample)
ZA (1) ZA200100622B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127419A (en) * 1998-11-23 2000-10-03 Burzynski; Stanislaw R. Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis
ES2333337T3 (es) * 2000-08-29 2010-02-19 Biocon Limited Uso de una composicion farmaceutica que contiene un derivado de acido para-aminofenilacetico para tratar afecciones inflamatorias del tracto gastrointestinal.
US8048924B2 (en) 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
US7087219B2 (en) * 2003-05-28 2006-08-08 Stanislaw R. Burzynski Toothpaste containing anticancer agents
US20060246016A1 (en) * 2003-05-28 2006-11-02 Burzynski Stanislaw R Toothpaste containing anticancer agents
US7772108B2 (en) * 2004-06-25 2010-08-10 Samsung Electronics Co., Ltd. Interconnection structures for semiconductor devices and methods of forming the same
DK1773767T3 (en) 2004-07-07 2016-03-21 Biocon Ltd Synthesis of azo bound in immune regulatory relations
CA2575367A1 (en) * 2004-07-28 2006-02-23 Board Of Regents, The University Of Texas System 3-halo-2-oxopropionate salts and esters as novel anticancer agents
JP5116479B2 (ja) 2004-11-26 2013-01-09 ユーシーエル ビジネス ピーエルシー オルニチンならびにフェニルアセテートまたはフェニルブチレートを含む、肝性脳症を治療するための組成物
US20060205818A1 (en) * 2005-03-08 2006-09-14 Burzynski Stanislaw R Method for the treatment of von Hippel-Lindau (VHL) disease with phenylacetyl-derivatives
ES2928586T3 (es) 2009-04-03 2022-11-21 Ocera Therapeutics Inc Fenilacetato de L-ornitina y métodos para elaborar el mismo
KR101715008B1 (ko) 2009-06-08 2017-03-22 유씨엘 비즈니스 피엘씨 Ｌ―오르니틴 페닐아세테이트를 사용한 문맥압 항진증의 치료 및 간 기능 회복
JP6087284B2 (ja) 2010-10-06 2017-03-01 オセラ セラピューティクス， インコーポレイテッド Ｌ−オルニチンフェニルアセテートを製造するための方法
DK3223829T3 (da) 2014-11-24 2020-02-10 Ucl Business Ltd Behandling af sygdomme associeret med hepatisk stellat-celleaktivering under anvendelse af ammoniak-sænkende terapier
HK1249434A1 (zh) 2015-08-18 2018-11-02 Ocera Therapeutics, Inc. 使用与苯乙酸盐和苯丁酸盐中的至少一种组合的l-鸟氨酸治疗和预防肌肉损失
WO2017114686A1 (en) * 2015-12-30 2017-07-06 Nestec S.A. Method for determining fat free body mass
US10624869B2 (en) 2017-05-08 2020-04-21 Stanislaw R. Burzynski Methods for the treatment of recurrent glioblastoma (RGBM)
CA3063134A1 (en) 2017-05-11 2018-11-15 Ocera Therapeutics, Inc. Processes of making l-ornithine phenylacetate
IL272422B2 (en) * 2017-06-12 2025-03-01 R Burzynski Stanislaw Methods for the treatment of leptomeningeal disease
US11344521B2 (en) 2017-06-12 2022-05-31 Burzynski Research Institute, Inc. Methods for the treatment of leptomeningeal disease
US20230190694A1 (en) * 2021-11-03 2023-06-22 Stanislaw R. Burzynski Compositions for and methods of precision cancer treatment
CN116019798B (zh) * 2022-07-20 2024-03-12 中南大学湘雅二医院 苯乙酰谷氨酰胺在制备预防和/或治疗阿霉素所致心脏毒性的药物中的应用
CN116491472B (zh) * 2022-12-14 2024-07-26 上海交通大学医学院附属第九人民医院 苯乙酰谷氨酰胺在构建慢性创面动物模型中的用途
WO2024263963A2 (en) * 2023-06-21 2024-12-26 Burzynski Stanislaw R Compositions comprising antineoplastons and methods of treating head and neck cancer
WO2024263960A2 (en) * 2023-06-21 2024-12-26 Burzynski Stanislaw R Compositions comprising antineoplastons and methods of treating lung cancer
WO2024263966A2 (en) * 2023-06-21 2024-12-26 Burzynski Stanislaw R Compositions comprising antineoplastons and methods of treating pancreatic cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4284647A (en) 1980-03-31 1981-08-18 The Johns Hopkins University Process for waste nitrogen removal
US4470970A (en) 1981-07-02 1984-09-11 Burzynski Stanislaw R Purified antineoplaston fractions and methods of treating neoplastic disease
US5244922A (en) * 1990-09-04 1993-09-14 Burzynski Stanislaw R Methods for treating viral infections
US5254587A (en) 1990-09-04 1993-10-19 Burzynski Stanislaw R Methods for treating AIDS
US5605930A (en) 1991-10-21 1997-02-25 The United States Of America As Represented By The Department Of Health And Human Services Compositions and methods for treating and preventing pathologies including cancer
ATE310505T1 (de) 1996-05-14 2005-12-15 Stanislaw R Burzynski Liposomale antineoplaston therapie mit bemerkenswert verbesserter antineoplastischer aktivität

Also Published As

Publication number Publication date
PL213698B1 (pl) 2013-04-30
JP2011051993A (ja) 2011-03-17
CN1605334A (zh) 2005-04-13
KR20030027089A (ko) 2003-04-03
KR100417100B1 (ko) 2004-02-05
ES2214866T3 (es) 2004-09-16
US6943192B2 (en) 2005-09-13
KR100399658B1 (ko) 2003-09-29
KR20010071025A (ko) 2001-07-28
CN1660061A (zh) 2005-08-31
WO2000004894A3 (en) 2000-04-27
DE69914084D1 (de) 2004-02-12
CN1319010A (zh) 2001-10-24
AU4854299A (en) 2000-02-14
WO2000004894A2 (en) 2000-02-03
DE69914084T2 (de) 2004-10-28
PL345959A1 (en) 2002-01-14
CA2336945A1 (en) 2000-02-03
JP2002521329A (ja) 2002-07-16
KR20030027087A (ko) 2003-04-03
PT1098643E (pt) 2004-05-31
IL140848A0 (en) 2002-02-10
HK1037142A1 (en) 2002-02-01
EA200100168A1 (ru) 2001-08-27
US20010044466A1 (en) 2001-11-22
KR100414587B1 (ko) 2004-01-13
US6258849B1 (en) 2001-07-10
BR9912356A (pt) 2001-04-17
IL140848A (en) 2005-05-17
EA004179B1 (ru) 2004-02-26
CA2336945C (en) 2008-11-18
EP1098643B1 (en) 2004-01-07
CN1191064C (zh) 2005-03-02
NZ509244A (en) 2004-02-27
KR20030027088A (ko) 2003-04-03
CN100400039C (zh) 2008-07-09
AU759278B2 (en) 2003-04-10
EP1098643A2 (en) 2001-05-16
ZA200100622B (en) 2002-06-26
DK1098643T3 (da) 2004-05-24
KR100417101B1 (ko) 2004-02-05
ID28160A (id) 2001-05-10

Similar Documents

Publication Publication Date Title
ATE257378T1 (de) Phenylacetylglutamin, phenylacetylisoglutamin, und/oder phenylacetat zur behandlung von neoplastischen erkrankungen
DE69230112D1 (de) Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin
ATE241365T1 (de) Saccharid-enthaltende zubereitungen zur behandlung von alzheimerschen erkrankung und von weiteren amyloidosen
ATE219363T1 (de) Lösliche prodrugs von paclitaxel
DE69636343D1 (de) Verwendung von glu-trp dipeptiden zur herstellung eines arzneimittels zur behandlung von verschiedenen gefässneubildung-assozierten erkrankungen
ATE73331T1 (de) Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus.
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
ATE322283T1 (de) Transdermale verwendung von sekretin zur behandlung von autismus
EA200000468A1 (ru) Терапевтическая композиция для введения толтеродина с контролируемым высвобождением
ATE450265T1 (de) Pharmazeutische mischung zur behandlung von krebs,die dioxolan nukleosidanalogen enthält
ATE375341T1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
ATE62414T1 (de) Mittel zur behandlung von herzerkrankungen.
DE58901002D1 (de) Mittel mit zerstoerender wirkung auf maligne tumore, verfahren zu dessen herstellung und praeparation zur anwendung in der therapie von krebskranken.
BR9813318A (pt) Processo de tratamento de tumores e degeneração macular em paciente humano ou veterinário, composição farmacêutica para tratamento de tumores e degeneração macular em um paciente humano ou veterinário
ATE193442T1 (de) 3,4-diarylchromane zur behandlung von dermatitis
ATE77751T1 (de) Mittel zur behandlung von knochenkrankheiten.
DE69428995D1 (de) Verfahren zur behandlung von neoplastischen erkrankungen unter verwendung von tiazofurin und ribavirin
BR0212249A (pt) Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, e, uso de um composto
DE60108130D1 (de) Pharmazeutische zusammensetzungen zur behandlung von neurologischen krankheiten
DE50103012D1 (de) Verwendung von hyaluronidase zur prophylaxe und behandlung von herz-kreislauf-erkrankungen
DE69943240D1 (de) Verwendung von HGF für die Behandlung von ischämischen Erkrankungen der Extremitäten
DE69312297D1 (de) Verwendung von 2-[4-(-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphtoquinon zur behandlung von krebs
DE69428797D1 (de) Verwendung von benzydamin zur behandlung von krankheitszuständen, die durch tnf verursacht werden
DE69434002D1 (de) 2,3 diaryl-1-benzopyrame zur behandlung von dermatitis
ATE335494T1 (de) Verwendung von n-glycolneuraminsäure und deren derivaten zur herstellung eines medikaments zur behandlung von hiv-infektionen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1098643

Country of ref document: EP